Inge Marie Svane
Clinical Professor
ORCID: 0000-0002-9451-6037
11 - 12 out of 12Page size: 10
- 2010
- Published
Therapeutic Vaccination Targeting Indoleamine-2, 3 Dioxygenase (IDO) Using a IDO Derived Class I Restricted Peptide in Combination with Aldara and Montanide for Patients With Locally Advanced or Metastatic Non Small-Cell Lung Cancer. A First-in-man Phase I Trial
Buch-Hansen, T. Z., Sørensen, R. B., Mellemgaard, A., Straten, P. T., Andersen, Mads Hald, Svane, Inge Marie & Andersen, Mads Hald, 2010, In: Journal of Immunotherapy. 33, 8, p. 919-920 2 p.Research output: Contribution to journal › Conference abstract in journal › Research › peer-review
- Published
Therapeutic cancer vaccines
Larsen, S. K., Svane, Inge Marie, Straten, P. T. & Andersen, Mads Hald, 2010, In: Current Cancer Therapy Reviews. 6, 2, p. 163-174Research output: Contribution to journal › Journal article › Research › peer-review
ID: 4054758
Most downloads
-
277
downloads
Mutational and putative neoantigen load predict clinical benefit of adoptive T cell therapy in melanoma
Research output: Contribution to journal › Journal article › Research › peer-review
Published -
257
downloads
T cell recognition of novel shared breast cancer antigens is frequently observed in peripheral blood of breast cancer patients
Research output: Contribution to journal › Journal article › Research › peer-review
Published -
189
downloads
Survival of metastatic melanoma patients after dendritic cell vaccination correlates with expression of leukocyte phosphatidylethanolamine-binding protein 1/Raf kinase inhibitory protein
Research output: Contribution to journal › Journal article › Research › peer-review
Published